<DOC>
	<DOCNO>NCT02511873</DOCNO>
	<brief_summary>This Phase II , 2 arm randomize crossover study . Subjects assign either active agent placebo crossover arm . This study design evaluate whether Fycompa improve quality life patient small fiber neuropathy .</brief_summary>
	<brief_title>Fycompa Subjects With Small Fiber Neuropathy ( SFN )</brief_title>
	<detailed_description>This study enroll 30 patient center alone proven SFN diagnosis skin biopsy assessment intraepidermal nerve fiber density . The patient must also pain score least 5 VAS Scale . Patients receive Fycompa 2mg tablet . Each week patient allow titrate 2mgs maximum dose 8mg day . This dosing use numerous pain study single dose proven effective . This seem reduce validity placebo phase . Patients choose dose feel best tolerate efficacious . Once patient choose dose randomize two arm . Each arm last 6 week . Such patient receive dose choose efficacious 6 week match placebo 6 week . Then patient crossover arm . Investigator assess compliance count pill visit . This provide ability see dose patient prefer study dose blind randomized fashion . There 5 office visit 3 phone visit study . Patients keep diary weekly VAS pain score .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Erythromelalgia</mesh_term>
	<mesh_term>Excitatory Amino Acid Antagonists</mesh_term>
	<criteria>1 . Small Fiber Neuropathy ( SFN ) proven skin biopsy assessment intraepidermal nerve fiber density . 2 . Pain score least 5 VAS scale . 3 . Male Female 18 60 year old . 4 . Subjects willing able comply schedule visit , treatment plan , laboratory test study procedure . 5 . Stable dose current pain medication medication use SFN 60 day prior screen . 6 . Women reproductive age must agree use doublebarrier method contraception . 1 . History intolerance hypersensitivity Fycompa . 2 . History psychosis , drug alcohol abuse within last 2 year . 3 . Malignancy within last 2 year ( except skin cancer ) . 4 . Clinically significant condition ( include limit cardiovascular hepatic disease seizure disorder ) . 5 . Pregnant female , breastfeed female , female childbearing potential use effective contraception . 6 . Subjects severe pain condition may impair selfassessment pain due SFN . 7 . Exclusion medication study : Carbamazepine , Carbatrol , Tegretol , Tegretol XR , Equetro , Epitol , Phenytoin , Dilantin , Phenytek , Oxcarbazepine , Trileptal , Rifampin , Refadin , Rimactane St. John Wort . 8 . Subjects renal impairment hemodialysis hepatic impairment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Fycompa</keyword>
	<keyword>Small Fiber Neuropathy</keyword>
	<keyword>SFN</keyword>
	<keyword>Neuropathy</keyword>
	<keyword>Pain</keyword>
</DOC>